News & Events

Development of an industrial platform of CAR T cell immunotherapy - 2 marzo 2023

Noemi Moroni, Biagio De Angelis

Chimeric Antigen Receptors (CARs) are artificial receptors composed of a region targeting a specific antigen linked, through an intracytoplasmic domain, to the T cell activation domain CD3zeta chain (first-generation CAR). Sarcomas are rare mesenchymal tumors that include a variety of bone or soft-tissue tumors that affect all ages but are relatively more common in the pediatric age group, accounting for about 10-15% of childhood cancers. The CARSA project: "Chimeric Antigen Receptor for Sarcoma", has seen the development of innovative gene therapy prototypes based on the generation of innovative CAR T-cells for the treatment of sarcoma patients. The success of adoptive CAR T cell therapy for cancer has inspired researchers to develop CARs also for the treatment of infectious diseases, such as invasive aspergillosis. The TRAZIMAB project has seen the development of an industrial production process for the production of CAR retroviral vectors to genetically modified T cells against Aspergillus fumigatus.